Tools   Select Another Resource Report Type

http://www.inspiralis.com/

Commercial organization supplying topoisimerase products and services to the pharmaceutical industry and academia to aid research in the anti-infectives and anti-cancer markets. Their aim is to provide pharmaceutical companies, and others involved in drug development, with the necessary tools to develop and screen novel anti-infective and anti-cancer compounds. Products All their proteins are expressed as the native sequences without additional tags. The only exception is the M. tuberculosis gyrase which is currently produced with a C-terminal His tag. An untagged version of this protein will be available soon. * Topoisomerase Enzymes and Assay Kits * Specific Gyrase Protein Domains * DNA Substrates and Markers * Antibodies Services * Gel Based Assays * Medium / High Throughput Assay * Investigation protein DNA interaction ReDCaT chip

Proper citation: Inspiralis (RRID:SCR_004082) Copy   

•   Source: SciCrunch Registry

http://www.biomol-informatics.com/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on August 12, 2021. Technology based company in Madrid that offers consulting services on Bioinformatics in areas of research, diagnostics and pharmaceutical industry.

Proper citation: Biomol-Informatics (RRID:SCR_004081) Copy   

•   Source: SciCrunch Registry

http://www.mps-hamburg.com/

Full service Clinical Research Organization (CRO) in Hamburg, Germany, mainly focusing on phase-I and phase-IIa clinical trials. MPS owns 72 bed research clinic with 6 physicians and 15 nurses as permanent staff. MPS is experienced in performing all kind of early stage clinical trials, including first-in-man-trials, medical-devices-trials, nutraceutical and consumer-goods-trials. MPS holds active database of more than 17,000 healthy volunteers, plus hundreds of patients in special populations.

Proper citation: MPS Hamburg (RRID:SCR_004087) Copy   

•   Source: SciCrunch Registry

http://www.syncom.nl/

Independent contract research organization / small and medium sized enterprise (CRO/SME) that assists pharma and biotechnology companies with medicinal chemistry programs, providing tailor-made custom synthesis solutions. Primary activities include synthesis of key building blocks, route scouting services, process research activities, scale up, medicinal chemistry services and hit-to-lead optimization. On custom basis they also synthesize metabolites, impurities, reference standards and stable labelled compounds. Their services are backed up by state-of-the-art analytical technologies such as HPLC, GC, LC-MS, GC-MS and NMR. These technologies can be offered as stand-alone analytical services as well. Syncom also has expertise in chiral technology. The firm has designed and synthesized numerous unique scaffolds, yielding many patent applications and clinical candidates. Name changed to Symeres after merger with Mercachem., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Syncom (RRID:SCR_004118) Copy   

•   Source: SciCrunch Registry

http://www.edelris.com/

A commercial medicinal chemistry company dedicated to the design and synthesis of natural product-mimetic screening compounds, Hit-to-Lead & Lead Optimization projects and Custom Synthesis. Aiming at the acceleration of the lead discovery and optimization process in pharma and biotech research organizations, EDELRIS uses its validated chemistry and drug discovery expertise to provide novelty to its customers with exclusive or non-exclusive small molecules and with efficient hit-to-lead optimization capabilities. EDELRIS has a wide range of services and based on its experience in various and complementary fields, the team is capable to deliver innovative solutions to synthetic and medicinal chemistry problems faced by clients.

Proper citation: Edelris (RRID:SCR_004112) Copy   

•   Source: SciCrunch Registry

http://www.idbs.com/

Commercial provider of advanced software and solutions that helps R&D teams make discoveries. They provide organizations with the technology they need to securely capture, manage, share and exploit structured and unstructured data. Their technology and domain expertise enables users to link data to data, data to people and people to people to drive innovation, achieve faster time to market and improve margins. Their diverse customer list includes R&D driven international companies in pharmaceuticals, biotechnology, agricultural sciences, chemicals, consumer goods, energy, engineering, food and beverage, and healthcare.

Proper citation: IDBS (RRID:SCR_004077) Copy   

•   Source: SciCrunch Registry

http://www.phenosys.com/

A research- and development-oriented company based in Berlin that engineers and markets technology for animal behavior research offering unique, automated instrumentation. This includes specialized applications of virtual reality and touch screen technology for animal behavior environments and RFID (transponder) operated devices in home cage environments. Their experimental systems are used for behavioral phenotyping, brain research, experimental psychology, and the diagnostic characterization of animal models for translational medicine.

Proper citation: PhenoSys (RRID:SCR_004072) Copy   

•   Source: SciCrunch Registry

http://www.noldus.com/

Commercial organization that develops tools and systems for measurement and analysis of animal and human behavior. They develop instrumented home cage systems, in which rodent behavior and ultrasonic vocalizations can be measured in a non-intrusive manner. Furthermore, they develop computer vision and pattern recognition technology for automated behavior detection. They believe that this approach has significant potential in research on animal models for Autism Spectrum Disorder.

Proper citation: Noldus (RRID:SCR_004074) Copy   

•   Source: SciCrunch Registry

http://www.korea.edu

Korea University is a private research university in Seoul, South Korea. Established in 1905, Korea University is one of the nation oldest and most prominent institutions of higher education. The student body consists of over 20,000 undergraduate students and over 10,000 graduate students. Korea University consists of the Seoul Campus, Sejong Campus and three auxiliary hospitals (Anam Hospital, Guro Hospital, Ansan Hospital).

Proper citation: Korea University; Seoul; South Korea (RRID:SCR_004095) Copy   

•   Source: SciCrunch Registry

http://www.biostat.jhsph.edu/~hji/cisgenome/index.htm

Integrated software tool for tiling array, ChIP-seq, genome and cis-regulatory element analysis.

Proper citation: CisGenome (RRID:SCR_001558) Copy   

•   Source: SciCrunch Registry

http://www.bioconductor.org/packages/release/bioc/html/vsn.html

Software package that implements a method for normalizing microarray intensities, both between colours within array, and between arrays. The method uses a robust variant of the maximum-likelihood estimator for the stochastic model of microarray data described in the references. The model incorporates data calibration (a.k.a. normalization), a model for the dependence of the variance on the mean intensity, and a variance stabilizing data transformation. Differences between transformed intensities are analogous to normalized log-ratios. However, in contrast to the latter, their variance is independent of the mean, and they are usually more sensitive and specific in detecting differential transcription.

Proper citation: vsn (RRID:SCR_001459) Copy   

•   Source: SciCrunch Registry

https://wiki.phenoscape.org/wiki/Teleost_Anatomy_Ontology

A multi-species anatomy ontology for teleost fishes. It was originally seeded from ZFA, but covers terms relevant to other taxa. The TAO uses terms from the Common Anatomy Reference Ontology (CARO) as a template for its upper level nodes, and the Vertebrate Skeletal Anatomy Ontology (VSAO) for general skeletal anatomy classes. Growth of the TAO is enabled by contributions from data curators and the ichthyological community. The TAO can be browsed by using the NCBO BioPortal and data annotated using TAO terms can be queried using the Phenoscape Knowedgebase.

Proper citation: Teleost Anatomy Ontology (RRID:SCR_001610) Copy   

•   Source: SciCrunch Registry

https://github.com/nolanlab/cytospade

Cytoscape plugin that provides a high-performance implementation of an interface for the Spanning-tree Progression Analysis of Density-normalized Events (SPADE) algorithm for tree-based analysis and visualization of high-dimensional cytometry data.

Proper citation: CytoSPADE (RRID:SCR_001457) Copy   

•   Source: SciCrunch Registry

http://www.bari2d.org/

A multicenter randomized clinical trial that aims to determine the best therapies for people with type 2 diabetes and moderately severe cardiovascular disease. 2368 participants were randomized at 49 sites in 6 countries. All subjects were given intensive medical therapy to control cholesterol and blood pressure and given counseling, if needed, to quit smoking and to lose weight. Beyond that, they compared whether prompt revascularization, either bypass surgery or angioplasty, e.g. stents, was more effective than medical therapy alone. At the same time, they also looked at which of two diabetes treatment strategies resulted in better outcomes����??insulin-providing versus insulin-sensitizing - that is, increasing the amount of insulin or making the insulin work better. Only patients with known type 2 diabetes and heart disease that could be treated appropriately with a revascularization OR medical therapy alone were eligible for the trial. Patients entered the study between January 2001 ����?? March 2005 and were followed for an average of five years. When a patient entered the study, physicians first decided whether that patient should receive stenting or bypass surgery. The patient then received their randomization assignment. All patients were treated in BARI 2D for both their diabetes and heart disease, as well as other risk factors that might effect those diseases, regardless of which group they were in. Diabetes-specific complications including retinopathy, nephropathy, neuropathy, and peripheral vascular disease were monitored regularly. Tests, blood samples, urine samples, and treatment cost data were obtained periodically through the trial and examined by experts at 7 central laboratories and other research partners. Experts on risk factors routinely oversaw treatments of all patients at 4 central management centers. A panel of independent experts reviewed data every six months to make sure that all patients were receiving safe care.

Proper citation: BARI 2D (RRID:SCR_001496) Copy   

•   Source: SciCrunch Registry

http://jdrf.org/

Global funder of type 1 diabetes (T1D) research that aims to progressively remove the impact of T1D from people's lives until a world without T1D is achieved. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. More than 80 percent of JDRF's expenditures directly support research and research-related education. In 2012 Forbes magazine named JDRF one of its five All-Star charities, citing the organization's efficiency and effectiveness. The organization awards research grants for laboratory and clinical investigations and sponsors a variety of career development and research training programs for new and established investigators. JDRF also sponsors international workshops and conferences for biomedical researchers. Individual chapters offer support groups and other activities for families affected by diabetes.

Proper citation: Juvenile Diabetes Research Foundation (RRID:SCR_001522) Copy   

•   Source: SciCrunch Registry

https://www.ara.com/mppd/

Computational model that can be used for estimating human and rat airway particle dosimetry. The model is applicable to risk assessment, research, and education. The MPPD model calculates the deposition and clearance of monodisperse and polydisperse aerosols in the respiratory tracts of rats and human adults and children (deposition only) for particles ranging in size from ultrafine (0.01 micrometers) to coarse (20 micrometers). The models are based on single-path and multiple-path methods for tracking air flow and calculating aerosol deposition in the lung. The single-path method calculates deposition in a typical path per airway generation, while the multiple-path method calculates particle deposition in all airways of the lung and provides lobar-specific and airway-specific information. Within each airway, deposition is calculated using theoretically derived efficiencies for deposition by diffusion, sedimentation, and impaction within the airway or airway bifurcation. Filtration of aerosols by the nose and mouth is determined using empirical efficiency functions. The MPPD model includes calculations of particle clearance in the lung following deposition.

Proper citation: Multiple-Path Particle Dosimetry Model (RRID:SCR_001486) Copy   

•   Source: SciCrunch Registry

http://www.jaeb.org/

Freestanding, nonprofit coordinating center for multi-center clinical trials and epidemiologic research that focus on projects involving eye disorders or type 1 diabetes.

Proper citation: Jaeb Center for Health Research (RRID:SCR_001513) Copy   

•   Source: SciCrunch Registry

http://wordpress.org/

Web software which helps users create a website or blog. WordPress software can be downloaded and installed with an appropriate web host and minimum requirements. There is also a service called WordPress.com which allows users to get started with a new and free WordPress-based blog in seconds, though it varies in several ways and is less flexible than the self-installed WordPress. An array of plugins and themes are available to further customize a site.

Proper citation: WordPress (RRID:SCR_001518) Copy   

•   Source: SciCrunch Registry

http://www.trigr.org

International, randomized, double-blinded trial to determine whether weaning to a casein hydrolysate formula during the first 6-8 months of life in place of cow milk based formula reduces the incidence of autoimmunity and type 1 diabetes in genetically susceptible newborn infants. 2160 eligible infants were randomized to test or control formulas when mothers decide to wean from exclusive breastfeeding. The participants will be monitored up to the age of 10 years for the appearance of diabetes-predictive autoantibodies and clinical type 1 diabetes. The TRIGR trial will determine whether delayed exposure to intact food proteins will reduce the chances of developing type 1 diabetes later in life. All babies in the study received the recommendation to breastfeed for at least the first six months of life. If a mother was unable to exclusively breastfeed before the baby was 8 months of age, her child was randomly assigned to one of two groups. One group of these babies received a trial formula based on extensively hydrolyzed protein; the other group received another trial formula containing a smaller amount of hydrolyzed protein. In the hydrolyzed formula, the big protein molecules have been split into very small fragments to provide a source of nutritional amino acids, but the fragments are likely too small to stimulate the immune system. The TRIGR trial will also be able to analyze whether exclusive breastfeeding per se can reduce the risk of the children to develop type 1 diabetes.

Proper citation: TRIGR (RRID:SCR_001550) Copy   

•   Source: SciCrunch Registry

https://repository.niddk.nih.gov/study/67

Clinical trial under the Urinary Incontinence Treatment Network to compare the treatment success for two surgical procedures that are frequently used and have similar cure rates, yet have not been compared directly to each other in a large, rigorously conducted randomized trial. The secondary aims of the trial are to compare other outcomes for the two surgical procedures, including quality of life, sexual function, satisfaction with treatment outcomes, complications, and need for other treatment(s) after surgery. Follow-up will be a minimum of two years and up to four years.

Proper citation: SISTEr (RRID:SCR_001542) Copy   

•   Source: SciCrunch Registry